{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:06:26Z","timestamp":1775862386399,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lecture's fee"},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Viatris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate whether the topical administration of ripasudil ophthalmic solution enhances aqueous outflow in the episcleral vein of the human eye. Two-sequence, prospective, randomized, double-blind, crossover trial. Sixteen eyes of 16 healthy participants were recruited in this study. Participants were randomized into one of the two crossover sequences to the instillation of ripasudil or the control drug, latanoprost, followed by a washout period of more than 2\u00a0days, and crossed over to the alternative instillation. The aqueous columns in the episcleral veins were recorded using a video capture system connected to a slit-light microscope (hemoglobin video imaging) before and 2 and 8\u00a0h after the instillation. Comparisons between ripasudil and latanoprost for the changes of the aqueous column width after the instillation. Two hours after the instillation, the ripasudil group had significantly greater dilation of the aqueous column width than the latanoprost group. Eight hours after the instillation, the ripasudil group had significantly greater dilation of the aqueous column width than the latanoprost group. Hemoglobin video imaging revealed that the topical administration of ripasudil ophthalmic solution enhanced aqueous outflow in the episcleral vein of the human eye.<\/jats:p>","DOI":"10.1038\/s41598-022-19271-9","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T10:04:50Z","timestamp":1662804290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aqueous column changes in the episcleral veins after the instillation of ripasudil versus latanoprost: a randomized, double-blind, crossover clinical trial"],"prefix":"10.1038","volume":"12","author":[{"given":"Marie","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Orii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Inatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"19271_CR1","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde, S. J. et al. Primary open-angle glaucoma preferred practice pattern\u00ae. Ophthalmology 128, P71\u2013P150 (2021).","journal-title":"Ophthalmology"},{"key":"19271_CR2","doi-asserted-by":"publisher","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko, Y. et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci. Rep. 6, 19640 (2016).","journal-title":"Sci. Rep."},{"key":"19271_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","volume":"787","author":"G Li","year":"2016","unstructured":"Li, G. et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur. J. Pharmacol. 787, 20\u201331 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"19271_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/jop.2014.0146","volume":"31","author":"JW Kiel","year":"2015","unstructured":"Kiel, J. W. & Kopczynski, C. C. Effect of AR-13324 on episcleral venous pressure in Dutch Belted rabbits. J. Ocul. Pharmacol. Ther. 31, 146\u2013151 (2015).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"19271_CR5","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2016","unstructured":"Ren, R. et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest. Ophthalmol. Vis. Sci. 57, 6197\u20136209 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"19271_CR6","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.3390\/jcm9124016","volume":"9","author":"T Akagi","year":"2020","unstructured":"Akagi, T. et al. Short-term effects of different types of anti-glaucoma eyedrop on the sclero-conjunctival vasculature assessed using anterior segment OCTA in normal human eyes: A pilot study. J. Clin. Med. 9, 4016 (2020).","journal-title":"J. Clin. Med."},{"key":"19271_CR7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0002-9394(42)90325-8","volume":"25","author":"KW Ascher","year":"1942","unstructured":"Ascher, K. W. The aqueous veins. Am. J. Ophthalmol. 25, 1174\u20131209 (1942).","journal-title":"Am. J. Ophthalmol."},{"key":"19271_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2019.04.001","volume":"2","author":"Z Tasneem","year":"2019","unstructured":"Tasneem, Z. et al. Hemoglobin video imaging provides novel in vivo high-resolution imaging and quantification of human aqueous outflow in patients with glaucoma. Ophthalmol. Glaucoma 2, 327\u2013335 (2019).","journal-title":"Ophthalmol. Glaucoma"},{"key":"19271_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/IJG.0000000000000799","volume":"26","author":"C Bostan","year":"2017","unstructured":"Bostan, C. & Harasymowycz, P. Episcleral venous outflow: A potential outcome marker for iStent surgery. J. Glaucoma 26, 1114\u20131119 (2017).","journal-title":"J. Glaucoma"},{"key":"19271_CR10","volume-title":"Zichtbare Afvoer van het Kamerwater","author":"S De Vries","year":"1947","unstructured":"De Vries, S. Zichtbare Afvoer van het Kamerwater (Drukkerij Kinsbergen, 1947)."},{"key":"19271_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.exer.2005.07.006","volume":"82","author":"T Koga","year":"2006","unstructured":"Koga, T. et al. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp. Eye Res. 82, 362\u2013370 (2006).","journal-title":"Exp. Eye Res."},{"key":"19271_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/bjophthalmol-2018-312991","volume":"104","author":"M Okamoto","year":"2020","unstructured":"Okamoto, M. et al. Rho-associated protein kinase inhibitor induced morphological changes in type VI collagen in the human trabecular meshwork. Br. J. Ophthalmol. 104, 392\u2013397 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"19271_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02173538","volume":"222","author":"G Giuffr\u00e8","year":"1985","unstructured":"Giuffr\u00e8, G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch. Clin. Exp. Ophthalmol. 222, 139\u2013141 (1985).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"19271_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1076\/ceyr.16.9.886.5038","volume":"16","author":"M Astin","year":"1997","unstructured":"Astin, M. & Stjernschantz, J. Mediation of prostaglandin F2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits. Curr. Eye Res. 16, 886\u2013890 (1997).","journal-title":"Curr. Eye Res."},{"key":"19271_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara, H. et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol. 126, 309\u2013315 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"19271_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara, H. et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 131, 1288\u20131295 (2013).","journal-title":"JAMA Ophthalmol."},{"key":"19271_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe, T. et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr. Eye Res. 39, 813\u2013822 (2014).","journal-title":"Curr. Eye Res."},{"key":"19271_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","volume":"34","author":"NA Mehran","year":"2020","unstructured":"Mehran, N. A. et al. New glaucoma medications: Latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond) 34, 72\u201388 (2020).","journal-title":"Eye (Lond)"},{"key":"19271_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajo.2015.01.026","volume":"159","author":"B Levy","year":"2015","unstructured":"Levy, B., Ramirez, N., Novack, G. D. & Kopczynski, C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am. J. Ophthalmol. 159, 980\u20135.e1 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"19271_CR20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/IJG.0b013e31825af0eb","volume":"22","author":"L Beltran-Agullo","year":"2013","unstructured":"Beltran-Agullo, L. et al. The effect of selective laser trabeculoplasty on aqueous humor dynamics in patients with ocular hypertension and primary open-angle glaucoma. J. Glaucoma 22, 746\u2013749 (2013).","journal-title":"J. Glaucoma"},{"key":"19271_CR21","doi-asserted-by":"publisher","first-page":"C44","DOI":"10.1152\/ajpcell.00024.2018","volume":"315","author":"F McDonnell","year":"2018","unstructured":"McDonnell, F., Dismuke, W. M., Overby, D. R. & Stamer, W. D. Pharmacological regulation of outflow resistance distal to Schlemm\u2019s canal. Am. J. Physiol. Cell Physiol. 315, C44\u2013C51 (2018).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"19271_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12886-020-01490-1","volume":"20","author":"H Tanihara","year":"2020","unstructured":"Tanihara, H., Kakuda, T., Sano, T., Kanno, T. & Gunji, R. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study. BMC Ophthalmol. 20, 275 (2020).","journal-title":"BMC Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19271-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T10:07:24Z","timestamp":1662804444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19271-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.I. is responsible for submitting a competing financial interest statement on behalf of all authors of the paper. M.I.\u2019s work has been partially funded by Kowa, Viatris and lecture\u2019s fee. Y.T. also has been partially funded as lecture\u2019s fees. The other authors declare no potential conflict.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15255"}}